Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-08-22 , DOI: 10.1056/nejmoa2313906
Toni K Choueiri ₁ , Thomas Powles ₁ , Katriina Peltola ₁ , Guillermo de Velasco ₁ , Mauricio Burotto ₁ , Cristina Suarez ₁ , Pooja Ghatalia ₁ , Roberto Iacovelli ₁ , Elaine T Lam ₁ , Elena Verzoni ₁ , Mahmut Gümüş ₁ , Walter M Stadler ₁ , Christian Kollmannsberger ₁ , Bohuslav Melichar ₁ , Balaji Venugopal ₁ , Marine Gross-Goupil ₁ , Alexandr Poprach ₁ , Maria De Santis ₁ , Fabio A Schutz ₁ , Se Hoon Park ₁ , Dmitry A Nosov ₁ , Camillo Porta ₁ , Jae Lyun Lee ₁ , Xavier Garcia-Del-Muro ₁ , Elisa Biscaldi ₁ , Ray Manneh Kopp ₁ , Mototsugu Oya ₁ , Li He ₁ , Aobo Wang ₁ , Rodolfo F Perini ₁ , Donna Vickery ₁ , Laurence Albiges ₁ , Brian Rini ₁ ,

Affiliation

From Dana-Farber Cancer Institute, Boston (T.K.C.); Barts Cancer Centre, Queen Mary University of London BRC, Royal Free NHS Trust, London (T.P.), and Beatson West of Scotland Cancer Centre and the University of Glasgow, Glasgow (B.V.) - all in the United Kingdom; HUS Helsinki University Hospital, Comprehensive Cancer Center, Helsinki (K.P.); University Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid (G.V.), and Medical Oncology, Vall d´Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus (C.S.), and Institute Catalan of Oncology-ICO-IDIBELL University of Barcelona (X.G.-M.), Barcelona - all in Spain; Bradford Hill Clinical Research Center, Santiago, Chile (M.B.); Fox Chase Cancer Center, Philadelphia (P.G.); Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome (R.I.), Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (E.V.), the University of Bari "A. Moro" and Azienda Ospedaliera Policlinico di Bari, Bari (C.P.), and Fondazione Salvatore Maugeri clinica del lavoro, Pavia (E.B.) - all in Italy; the University of Colorado Cancer Center, Aurora (E.T.L.); Istanbul Medeniyet University, Prof. Dr. Suleyman Yalcin City Hospital, Istanbul, Turkey (M.G.); the University of Chicago Medical Center, Chicago (W.M.S.); BC Cancer-Vancouver Center, Vancouver, BC, Canada (C.K.); the Department of Oncology, Palacký University and University Hospital, Olomouc (B.M.), and the Department of Comprehensive Cancer Care and Faculty of Medicine, Masaryk Memorial Cancer Institute and Masaryk University, Brno (A.P.) - both in the Czech Republic; University Hospital Bordeaux-Hôpital Saint-André, Bordeaux (M.G.-G.), and Département de Médecine Oncologique, Gustave Roussy, Université Paris Saclay, Villejuif (L.A.) - both in France; Charité Universitaetsmedizin Berlin, Department of Urology, Berlin (M.D.S.); the Department of Urology, Medical University of Vienna, Vienna (M.D.S.); BP-A Beneficencia Portuguesa de São Paulo, Sao Paulo (F.A.S.); Samsung Medical Center, Sungkyunkwan University School of Medicine (S.H.P.), and Asan Medical Center, University of Ulsan College of Medicine (J.L.L.) - both in Seoul, South Korea; Central Clinical Hospital with Polyclinic, Moscow (D.A.N.); Sociedad de Oncología y Hematología del Cesar, Valledupar, Colombia (R.M.K.); Keio University Hospital, Tokyo (M.O.); Merck, Rahway, NJ (L.H., A.W., R.F.P., D.V.); and Vanderbilt Ingram Cancer Center, Nashville (B.R.).

Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies.In a phase 3, multicenter, open-label, active-controlled tria...

中文翻译：